# Membrane-Anchored Serine Protease Inhibitors: Physiological Functions, Mechanisms, and Roles in Cancer

**Authors:** Chun-Ying Chen, Tai-No Lin, Hsiang-Po Huang

PMC · DOI: 10.3390/ijms27042000 · International Journal of Molecular Sciences · 2026-02-19

## TL;DR

This review explores how HAI-1 and HAI-2 regulate proteases in tissue health and cancer, highlighting their roles as tumor suppressors and potential therapeutic targets.

## Contribution

The paper provides a comprehensive review of the physiological and cancer-related functions of HAI-1 and HAI-2, emphasizing their context-dependent roles and therapeutic potential.

## Key findings

- HAI-1 and HAI-2 are critical for placental, skin, neural, and intestinal development.
- Downregulation of HAIs promotes cancer progression via activation of HGF/c-MET and PAR-2/NF-κB pathways.
- Reduced HAI levels in tumors correlate with metastasis and poor prognosis in several carcinomas.

## Abstract

Pericellular proteolysis is essential for maintaining tissue homeostasis. Central to this process are hepatocyte growth factor activator inhibitor-1 (HAI-1) and HAI-2, membrane-bound inhibitors that regulate type II transmembrane serine proteases, including matriptase and prostasin, through high-affinity Kunitz domains. This review summarizes current understanding of their molecular structures, physiological roles, and cancer-related clinical relevance. Genetic models reveal HAI-1 is critical for placental and skin development, while HAI-2 is crucial for neural tube closure and intestinal integrity. In cancer, HAIs generally act as tumor suppressors. Their downregulation, often via promoter hypermethylation, leads to excessive activation of hepatocyte growth factor/c-MET or protease-activated receptor-2/NF-κB signaling, promoting epithelial–mesenchymal transition and cancer progression. Clinically, reduced HAI levels in tumors correlate with metastasis and poor prognosis in several carcinomas. Paradoxically, elevated HAI expression in certain cancers suggests context-dependent pro-tumor functions. Emerging evidence links HAI loss to immune suppression, notably via M2 macrophage polarization in lung cancer. Finally, we highlight future directions for identifying tissue-specific serine proteases, downstream signaling, and therapeutic strategies, including recombinant mimetics and epigenetic reactivation, in precision oncology. In conclusion, HAI-1 and HAI-2 are key regulators of tissue homeostasis and cancer, with overlapping yet distinct functions, which present promising opportunities for therapeutic targeting.

## Linked entities

- **Genes:** SPINT1 (serine peptidase inhibitor, Kunitz type 1) [NCBI Gene 6692], SPINT2 (serine peptidase inhibitor, Kunitz type 2) [NCBI Gene 10653], St14 (suppression of tumorigenicity 14 (colon carcinoma)) [NCBI Gene 19143], PRSS8 (serine protease 8) [NCBI Gene 5652], MET (MET proto-oncogene, receptor tyrosine kinase) [NCBI Gene 4233], F2RL1 (F2R like trypsin receptor 1) [NCBI Gene 2150], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790]
- **Diseases:** cancer (MONDO:0004992), lung cancer (MONDO:0005138)

## Full-text entities

- **Genes:** F2RL1 (F2R like trypsin receptor 1) [NCBI Gene 2150] {aka GPR11, PAR2}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, TMPRSS13 (transmembrane serine protease 13) [NCBI Gene 84000] {aka MSP, MSPL, MSPS, TMPRSS11}, F2rl1 (F2R like trypsin receptor 1) [NCBI Gene 14063] {aka Gpcr11, PAR-2, Par2}, SOX9 (SRY-box transcription factor 9) [NCBI Gene 6662] {aka CMD1, CMPD1, ENH13, SRA1, SRXX2, SRXY10}, Mapk14 (mitogen-activated protein kinase 14) [NCBI Gene 26416] {aka CSBP2, Crk1, Csbp1, Mxi2, PRKM14, PRKM15}, HGFAC (HGF activator) [NCBI Gene 3083] {aka HGFA}, Flg (filaggrin) [NCBI Gene 14246] {aka ft}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, Par2 (pulmonary adenoma resistance 2) [NCBI Gene 109447], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, Spint2 (serine protease inhibitor, Kunitz type 2) [NCBI Gene 20733] {aka HAI-2}, Hjv (hemojuvelin BMP co-receptor) [NCBI Gene 69585] {aka 2310035L15Rik, 5230400G09Rik, DL-M, Hfe2, Rgmc, hemojuvelin}, Ctnnb1 (catenin beta 1) [NCBI Gene 12387] {aka Bfc, Catnb, Mesc}, ZEB2 (zinc finger E-box binding homeobox 2) [NCBI Gene 9839] {aka HSPC082, SIP-1, SIP1, SMADIP1, ZFHX1B}, SPINT2 (serine peptidase inhibitor, Kunitz type 2) [NCBI Gene 10653] {aka DIAR3, HAI-2, HAI2, Kop, PB}, Hgfac (hepatocyte growth factor activator) [NCBI Gene 54426] {aka HGFA}, SP1 (Sp1 transcription factor) [NCBI Gene 6667], SPINT1 (serine peptidase inhibitor, Kunitz type 1) [NCBI Gene 6692] {aka HAI, HAI1, MANSC2}, PLG (plasminogen) [NCBI Gene 5340] {aka HAE4}, MMP14 (matrix metallopeptidase 14) [NCBI Gene 4323] {aka MMP-14, MMP-X1, MT-MMP, MT-MMP 1, MT1-MMP, MT1MMP}, Spint1 (serine protease inhibitor, Kunitz type 1) [NCBI Gene 20732] {aka HAI-1}, Grhl2 (grainyhead like transcription factor 2) [NCBI Gene 252973] {aka 0610015A08Rik, BOM, Tcfcp2l3, clft3}, Prss8 (serine protease 8 (prostasin)) [NCBI Gene 76560] {aka 2410039E18Rik, CAP1, fr, mCAP1}, Cxcl12 (C-X-C motif chemokine ligand 12) [NCBI Gene 20315] {aka Pbsf, Scyb12, Sdf1, Tlsf, Tpar1}, CDX2 (caudal type homeobox 2) [NCBI Gene 1045] {aka CDX-3, CDX2/AS, CDX3}, CLDN1 (claudin 1) [NCBI Gene 9076] {aka CLD1, ILVASC, SEMP1}, EGR1 (early growth response 1) [NCBI Gene 1958] {aka AT225, G0S30, KROX-24, NGFI-A, TIS8, ZIF-268}, GFAP (glial fibrillary acidic protein) [NCBI Gene 2670] {aka ALXDRD}, ST14 (ST14 transmembrane serine protease matriptase) [NCBI Gene 6768] {aka ARCI11, CAP3, HAI, MT-SP1, MTSP1, PRSS14}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, MET (MET proto-oncogene, receptor tyrosine kinase) [NCBI Gene 4233] {aka AUTS9, DA11, DFNB97, HGFR, RCCP2, c-Met}, MMP7 (matrix metallopeptidase 7) [NCBI Gene 4316] {aka MMP-7, MPSL1, PUMP-1}, Mt2 (metallothionein 2) [NCBI Gene 17750] {aka MT-II, Mt-2}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, KLK4 (kallikrein related peptidase 4) [NCBI Gene 9622] {aka AI2A1, ARM1, EMSP, EMSP1, KLK-L1, PRSS17}, STAT6 (signal transducer and activator of transcription 6) [NCBI Gene 6778] {aka D12S1644, HIES6, IL-4-STAT, STAT6B, STAT6C}, Cdh1 (cadherin 1) [NCBI Gene 12550] {aka ARC-1, E-cad, Ecad, L-CAM, UVO, Um}, Hpn (hepsin) [NCBI Gene 15451] {aka Hlb320}, TACSTD2 (tumor associated calcium signal transducer 2) [NCBI Gene 4070] {aka EGP-1, EGP1, GA733-1, GA7331, GP50, M1S1}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, TMPRSS4 (transmembrane serine protease 4) [NCBI Gene 56649] {aka CAP2, CAPH2, MT-SP2, TMPRSS3}, Dnmt1 (DNA methyltransferase 1) [NCBI Gene 13433] {aka Cxxc9, Dnmt, Dnmt1o, MCMT, MTase, Met-1}, Tmprss6 (transmembrane serine protease 6) [NCBI Gene 71753] {aka 1300008A22Rik}, Hamp (hepcidin antimicrobial peptide) [NCBI Gene 84506] {aka Hamp1, Hepc, Hepc1}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, PRSS8 (serine protease 8) [NCBI Gene 5652] {aka CAP1, PROSTASIN}, TMPRSS2 (transmembrane serine protease 2) [NCBI Gene 7113] {aka PRSS10}, SLTM (SAFB like transcription modulator) [NCBI Gene 79811] {aka Met}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, Nphs2 (nephrosis 2, podocin) [NCBI Gene 170484] {aka PDCN, SRN1}, BMP1 (bone morphogenetic protein 1) [NCBI Gene 649] {aka OI13, PCOLC, PCP, TLD}, St14 (suppression of tumorigenicity 14 (colon carcinoma)) [NCBI Gene 19143] {aka Epithin, MT-SP1, Prss14, Tmprss14, mCAP3, matriptase}, BMP2 (bone morphogenetic protein 2) [NCBI Gene 650] {aka BDA2, BMP2A, SSFSC, SSFSC1}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, CA9 (carbonic anhydrase 9) [NCBI Gene 768] {aka CAIX, MN}, LDLR (low density lipoprotein receptor) [NCBI Gene 3949] {aka LDLCQ2}, Hgf (hepatocyte growth factor) [NCBI Gene 15234] {aka C230052L06Rik, HGF/SF, NK1, NK2, SF, SF/HGF}
- **Diseases:** epidermal acanthosis (MESH:D004814), injury to (MESH:D014947), neurodegenerative diseases (MESH:D019636), embryonic lethality (MESH:D020964), chronic inflammation (MESH:D007249), PCa (MESH:D011471), CPE (MESH:D009375), breast, prostate, gastric, and pancreatic cancers (MESH:C537243), gliomas (MESH:D005910), congenital ichthyosis (MESH:C538281), distant metastasis (MESH:D009362), acute injury (MESH:D001930), influenza (MESH:D007251), cervical carcinoma (MESH:D002583), Spint2 deficiency (MESH:D007153), leukemia (MESH:D007938), placental labyrinth abnormalities (MESH:D007762), colorectal and lung cancers (MESH:D015179), HAI insufficiency (MESH:D006130), Pancreas (MESH:D010190), placental failure (MESH:D051437), AD (MESH:D000544), multiple myeloma (MESH:D009101), bladder, liver, and lung cancers (MESH:D008175), diabetes (MESH:D003920), embryonic defects (MESH:D018236), placental and (MESH:D010922), lung (MESH:D008171), colitis (MESH:D003092), SCSD (MESH:C562576), cerebral infarction (MESH:D002544), Cancer (MESH:D009369), nodal (MESH:D013611), toxicity (MESH:D064420), cystic fibrosis (MESH:D003550), hair (MESH:D006201), developmental (MESH:C567924), esophageal squamous cell carcinoma (MESH:D000077277), lethality (MESH:C536057), HAIs (MESH:D006255), chronic kidney disease (MESH:D051436), chronic hepatitis C virus infection (MESH:D019698), TAD (MESH:D000094629), infarct (MESH:D007238), tufting enteropathy (MESH:C567703), gastric cancer (MESH:D013274), hypoxic (MESH:D002534), breast and hepatocellular carcinomas (MESH:D001943), inflammatory bowel disease (MESH:D015212), nephropathy (MESH:D007674), dementia (MESH:D003704), Renal Function (MESH:D058186), histologic abnormalities (MESH:D009370), ovarian cancer (MESH:D010051), carcinogenesis (MESH:D063646), AML (MESH:D015470), HCC (MESH:D006528), genetic and metabolic diseases (MESH:D008659), neural tube (MESH:D009436), glucose intolerance (MESH:D018149)
- **Chemicals:** 5-aza (-), H2O2 (MESH:D006861), guadecitabine (MESH:C580831), epirubicin (MESH:D015251), adriamycin (MESH:D004317), sodium (MESH:D012964), Disulfide (MESH:D004220), cholesterol sulfate (MESH:C007045), lipid (MESH:D008055), Iron (MESH:D007501), 4-hydroxy-2-nonenal (MESH:C027576), Glucose (MESH:D005947), CoCl2 (MESH:C018021), 5-aza-2'-deoxycytidine (MESH:D000077209), 5-azacytidine (MESH:D001374), cyclic AMP (MESH:D000242)
- **Species:** Malus domestica (apple, species) [taxon 3750], Danio rerio (leopard danio, species) [taxon 7955], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Sus scrofa (pig, species) [taxon 9823]
- **Mutations:** S238A, Y163C, rs2278431, G168S, BRAFV600E
- **Cell lines:** HLC-1 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_5529), SKBR3 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0033), Caco-2 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0025), HaCaT — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0038), BT474 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0179), WiDr — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_2760), BeWo — Homo sapiens (Human), Gestational choriocarcinoma, Cancer cell line (CVCL_0044)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940448/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940448/full.md

## References

171 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940448/full.md

---
Source: https://tomesphere.com/paper/PMC12940448